Spectral Diagnostics Inc. of Toronto has appointed ChristopherPlaxton executive vice president and Gregory Svanasoperations officer. Plaxton has been a partner with Coopers &Lybrand for the past 10 years and Svanas was a researchscientist at Miles Laboratories.
Lawrence Cohen was promoted to vice president of researchfrom senior director of molecular biology at Somatix TherapyCorp. of Alameda, Calif.
Cambridge NeuroScience Inc. President Elkan Gamzu willsucceed Alan Dalby as chief executive officer of the Cambridge,Mass., company. Dalby will serve as non-executive chairman ofthe board until his planned retirement in May 1994.
Centocor Inc. of Malvern, Pa., named Timothy Cost senior vicepresident of investor relations and strategic operations,effective Jan. 4. Cost is currently director of investor relationsat Eastman Kodak Co.
Carrington Laboratories Inc. of Irving, Texas, appointed CarltonTurner executive vice president of scientific affairs andpromoted Bill McAnalley to senior vice president of researchfrom vice president. Turner was president and chief executiveofficer of Princeton Diagnostic Laboratories of America.
Charles Bugg, a founder of BioCryst Pharmaceuticals Inc., hasbeen named chairman of the board and chief executive officerof the Birmingham, Ala., company. Bugg was the companyUsfirst chief executive officer, from 1987-88, and has beenchairman of the companyUs scientific advisory board in theintervening years.
Anthony Nicholls, president and chief executive officer ofTrinity Biotech of Dublin, Ireland, has been elected chairman ofthe board, replacing Denis Burger, who is retiring as chairman.Ronan OUCaoimh, the companyUs chief financial officer, willresume the role of president.
Matthew Haines has joined Oncogene Science Inc. of Uniondale,N.Y., as director of corporate communications. Haines wasdirector of investor relations at Cel-Sci Corp.
(c) 1997 American Health Consultants. All rights reserved.